Evidence map›Paper›PMID 29695609›Full record

ArticleMolecular pharmacology2018

Bitopic Binding Mode of an M

Sophie J Bradley, Colin Molloy, Christoffer Bundgaard, Adrian J Mogg, Karen J Thompson, Louis Dwomoh, Helen E Sanger, Michael D Crabtree, Simon M Brooke, Patrick M Sexton and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. MPharmacology research & perspectives · 2022
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Modulation of arousal and sleep/wake architecture by MNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Article
  11. Crosstalk between the MCellular signalling · 2020
    Review
  12. Article
  13. T-495, a novel low cooperative MPharmacology research & perspectives · 2020
    Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Sophie J BradleyThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Colin MolloyThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Christoffer BundgaardThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Adrian J MoggThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Karen J ThompsonThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Louis DwomohThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Helen E SangerThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Michael D CrabtreeThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Simon M BrookeThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Patrick M SextonThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Christian C FelderThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Arthur ChristopoulosThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Lisa M BroadThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.).
Andrew B TobinThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.) andrew.tobin@glasgow.ac.uk chris.langmead@monash.edu.
Christopher J LangmeadThe Centre for Translational Pharmacology, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland (S.J.B., C.M., K.J.T., L.D., S.M.B., A.B.T.); Eli Lilly & Co. Neuroscience, Windlesham, Surrey, United Kingdom (C.B., A.J.M., H.E.S., M.D.C., L.M.B.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.M.S., A.C., C.J.L.); and Eli Lilly & Co. Neuroscience, Indianapolis, Indiana (C.C.F.) andrew.tobin@glasgow.ac.uk chris.langmead@monash.edu.
Eli Lilly (United States) · USUniversity of Glasgow · GBMonash University · AUEli Lilly (United Kingdom) · GB

Funding

Cancer Research UK C596/A17196Medical Research Council MR/P019366/1Wellcome TrustWellcome Trust 201529/Z/16/Z
6 · The paper itself

Abstract

The realization of the therapeutic potential of targeting the M

Indexed as

AcetylcholineAllosteric RegulationAllosteric SiteAlzheimer DiseaseAnimalsBenzimidazolesBinding SitesCell LineCHO CellsClinical Trials as TopicCricetinaeCricetulusHumansLearningMaleMemoryAcetylcholinebenzimidazol-2-oneBenzimidazolesGSK 1034702Muscarinic AgonistsReceptor, Muscarinic M1Receptors, Muscarinic

Identifiers

PMID29695609
PMCPMC5963591
OpenAlexW2800724524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.